Prilosec OTC Forced Name Change Rejected As FDA Clears Pending Petitions
This article was originally published in The Tan Sheet
A lack of data supporting consumer confusion claims between nonprescription Prilosec and the eponymous Rx version is cited by FDA in a letter denying a citizen petition. The petitioner sought an agency-mandated name change
You may also be interested in...
AstraZeneca appears to be building its case to ward off eventual private label competition for Prilosec OTC upon expiration of Hatch/Waxman exclusivity
FDA should require that Prilosec OTC be sold under a different brand name to "reduce the risk of consumer confusion" resulting from extensive direct-to-consumer advertising for the Rx version of the drug, an Aug. 12 citizen petition says
FDA's June 20 approval of Procter & Gamble/ AstraZeneca's Prilosec OTC permits the companies to sell the proton pump inhibitor in packages containing more than one 14-day treatment regimen